DATA AVAILABILITY STATEMENT
The data that supports the findings of this study are available in the
supplementary material of this article (Tables).
REFERENCES
- O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing:
criteria, detection and prevention. Drugs Aging. 2012; 29:437–52.
- Fu AZ, Jiang JZ, Reeves JH, et al. Potentially inappropriate
medication use and healthcare expenditures in the US
community-dwelling elderly. Med Care. 2007;45:472–476.
- Atkin PA, Veitch PC, Veitch EM, Ogle SJ. The epidemiology of serious
adverse drug reactions among the elderly. Drugs Aging.
1999;14:141–52.
- Beers
MH. Explicit criteria for determining potentially inappropriate
medication use by the elderly. An update.
Arch Intern Med.
1997 Jul;157(14):1531-6.
- Fick
DM,
Cooper
JW,
Wade
WE,
Waller
JL,
Maclean
JR,
Beers
MH. Updating the Beers criteria for potentially inappropriate
medication use in older adults: results of a US consensus panel of
experts. Arch
Intern Med. 2003 Dec; 8-22;163(22):2716-24.
- Rancourt C, Moisan J, Baillargeon L, et al. Potentially inappropriate
prescriptions for older patients in long-term care. BMC Geriatr. 2004;
15; 4: 9
- Holt S, Schmeidl S, Thurmann PA. Potentially inappropriate medications
in the elderly: the PRISCUS List. Dtsch Arztebl Int 2010; 107
(31–32): 543–51
- Rognstad S, Brekke M, Fetveit A, et al. The Norwegian General Practice
(NORGEP) criteria for assessing potentially inappropriate
prescriptions to elderly patients: a modified Delphi study. Scand J
Prim Health Care 2009; 27: 153–9
- Fick D, Semla T, Beizer J, et al. The American Geriatrics Society 2012
Beers Criteria Update Expert Panel. American Geriatrics Society
updated Beers criteria for potentially inappropriate medication use in
older adults. JAGS 2012. doi: 10.1111/j.1532–5415.2012. 03923.x
[online].
- Beers
MH,
Ouslander
JG,
Rollingher
I, et al. Explicit criteria for determining inappropriate medication
use in nursing home residents. UCLA Division of Geriatric Medicine.
1991; 151(9):1825-32.
- Hamilton
H,
Gallagher
P,
Ryan
C,et al. Potentially Inappropriate Medications Defined by STOPP
Criteria and the Risk of Adverse Drug Events in Older Hospitalized
Patients. Arch Intern Med. 2011;171(11):1013-1019.
- Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older
Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to
Right Treatment): consensus validation. Int J Clin Pharmacol Ther
2008; 46 (2): 72–83
- Delgado Silveira E.
Muñoz
García
M, Montero
Errasquin B, et al. Inappropriate prescription in older patients: the
STOPP/START criteria. Rev Esp Geriatr Gerontol. 2009; 44(5):273-9
- O’Mahony
D,
O’Sullivan
D,
Byrne
S, et al. STOPP/START criteria for potentially inappropriate
prescribing in older people: version 2.
Age
Ageing. 2015; 44(2): 213–218.)
- By
the American Geriatrics Society 2015 Beers Criteria Update Expert
Panel. American Geriatrics Society 2015 Updated Beers Criteria for
Potentially Inappropriate Medication Use in Older Adults.
J Am Geriatr Soc.
2015; 63(11):2227-46.
- Cahir
C, Bennett
K, Teljeur C, Fahey T. Potentially inappropriate prescribing and
adverse health outcomes in community dwelling older patients. Br J
Clin Pharmacol. 2014;77(1):201-10.
- Motl S, Timpe E, Eichner S. Proposal to improve MedWatch:
decentralized, regional surveillance of adverse drug reactions. Am J
Health Syst Pharm 2004;61:1840–2
- Blozik E, Born AM, Stuck AE, et al. Reduction of inappropriate
medications among older nursing-home residents: a nurse-led,
pre/post-design, intervention study. Drugs Aging. 2010;27:1009–17.
- Dunn RL, Harrison D, Ripley TL. The beers criteria as an outpatient
screening tool for potentially inappropriate medications. Consult
Pharm. 2011;26:754–63.
- Thomas
RE,
Thomas
BC. A systematic review of studies of the STOPP/START 2015 and
American Geriatric Society Beers 2015 criteria.
Curr Aging Sci.
2019; (2):121-154.
- Wing E. J. HIV and aging. Int J Infect Dis. 2016; 53, 61-68.
- Smi M,
Brinkman
K, Geerlings S, et al. Future challenges for clinical care of an
ageing population infected with HIV: a modelling study. Lancet InfecT
Dis. 2015; 15, 810-818.
- Ware D, Palella FJ Jr, Chew KW,
et
al. Prevalence and trends of polypharmacy among HIV-positive and
negative men in the multicenter AIDS cohort study from 2004 to 2016.
PLoS
One. 2018; 11;13(9):e0203890
- Guaraldi
G, Malagoli A, Calcagno A, et al. The increasing burden and complexity
of multi-morbidity and polypharmacy in geriatric HIV patients: a cross
sectional study of people aged 65 - 74 years and more than 75 years.
BMC Geriatr.
2018; 18, 99.
- Hasse B,
Ledergerber
B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the
Swiss HIV cohort study.
Clin
Infect Dis. 2011; 53, 1130-1139.
- Schouten J,
Wit
FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of
age-associated comorbidities and their risk factors between
HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin
Infect Dis. 2014; 59, 1787-1797.
- Greene
M,
Steinman
MA,
McNicholl
IR,
Valcour
VJ. Polypharmacy,
drug-drug interactions, and potentially inappropriate medications in
older adults with human immunodeficiency virus infection. Am Geriatr
Soc. 2014; 62(3):447-53.
- McNicholl
IR, Gandhi
M, Hare
CB, et al. A Pharmacist- Led program
Evaluate and Reduce Polypharmacy and Potentially InappropriatePrescribing in Older HIV-Positive Patients.
Pharmacotherapy. 2017;
37(12):1498-1506.
- Courlet
P, Livio F, Guidi M.
Swiss HIVCohort
Study. Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs:
New Challenges in the Aging Population
With HIV. Open
Forum Infect Dis. 2019; 21;6(12):ofz531.
-
Blanco JR, Morillo R, Abril V, et al.
Deprescribing of
non-antiretroviral therapy in HIV-infected patients. Eur J Clin
Pharmacol. 2020; 76(3):305-318.
-
Negredo
E, Back
D, Blanco
JR, et al. Aging in HIV-Infected Subjects: A New Scenario and a New
View. Biomed
Res Int. 2017; 2017:5897298.
-
Scott
LJ. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1
Infection. Drugs.
2020; 80(1):61-72.
-
van
Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of Switching to
Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing
a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for
Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3,
Randomized, Non-inferiority TANGO Study. Clin Infect Dis. 2020; pii:
ciz1243.
-
Dowers
E, Zamora
F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment
of HIV-1 infection.
Drugs. 2018;
2;10:215-224. 2018 Nov;78(16):1741-1750.
-
Aboud
M,
Orkin
C,
Podzamczer
D, et al. Efficacy and safety of dolutegravir-rilpivirine for
maintenance of virological suppression in adults with HIV-1: 100-week
data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2
studies. Lancet
HIV. 2019; 6(9):e576-e587.
-
Nozza
S,
Malagoli
A,
Maia
L, et al.
GEPPO
Study Group. Antiretroviral therapy in geriatric HIV patients: the
GEPPO cohort study.
J Antimicrob
Chemother. 2017; 72(10):2961.
-
By
the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel.
American Geriatrics Society Beers Criteria Update Expert Panel.
American Geriatrics Society 2019 Updated AGS Beers Criteria® for
potentially inappropriate medication use in older adults. J Am Geriatr
Soc 2019; 67: 674–94.
-
Livio
F, Marzolini C. Prescribing issues in older adults living with HIV:
thinking beyond drug–drug interactions with antiretroviral drugs.
2019; 10: 2042098619880122.